ACADIA PHARMACEUTICALS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.71 USD | +2.45% |
|
-0.65% | -46.63% |
| 04-23 | Neuren Pharmaceuticals' Medication Secures Priority Review from Health Canada | MT |
| 04-22 | Acadia Pharmaceuticals' Rett Syndrome Treatment Granted Priority Review by Health Canada | MT |
Chart calendar ACADIA Pharmaceuticals Inc.
a9688342af506a49bd3cb8.dUPjtX583-AM4ztU9_GIltxFSAc10PxF6QXvyTcL2wQ.Lxub7xkm5o9vh2IRwobN5aY8Ol90l89wkVWLhFV8lkMncbLgRzOmpEaGVA~3d4fc695f1e911df7adba7231215541d
Upcoming events on ACADIA Pharmaceuticals Inc.
Past events on ACADIA Pharmaceuticals Inc.
| 17/04/2024 23:54 | American Academy of Neurology Meeting - Abstract Number - 2877 |
| 17/04/2024 22:54 | American Academy of Neurology Meeting - Abstract Number - 3540 |
| 08/04/2024 20:45 | Needham Healthcare Conference |
| 18/03/2024 18:00 | UBS Virtual CNS Day |
| 06/03/2024 16:10 | TD Cowen Health Care Conference |
| 27/02/2024 21:30 | Q4 2023 Earnings Call |
| 27/02/2024 21:05 | Q4 2023 Earnings Release |
| 09/01/2024 17:00 | JPMorgan Healthcare Conference |
| 07/11/2023 21:30 | Guggenheim Securities Inflammation & Immunology Conference |
| 02/11/2023 20:30 | Q3 2023 Earnings Call |
| 02/11/2023 20:05 | Q3 2023 Earnings Release |
| 26/09/2023 16:40 | Cantor Global Healthcare Conference |
| 20/09/2023 22:00 | TD Cowen Novel Mechanisms in Neuropsychiatry Summit |
| 12/09/2023 17:15 | Morgan Stanley Global Healthcare Conference |
| 05/09/2023 | Citi BioPharma Conference |
| 02/08/2023 21:30 | Q2 2023 Earnings Call |
| 02/08/2023 21:05 | Q2 2023 Earnings Release |
| 13/07/2023 21:30 | Business Update Call |
| 13/06/2023 22:00 | ACP-101 Phase 3 Study Results Call |
| 07/06/2023 15:00 | Jefferies Global Healthcare Conference |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 339 338 0.45% | 442 444 -0.45% | 484 488 -0.79% | 517 516 0.29% | 726 719 1% | 967 |
|
EBITDA Million USD | Released Forecast Spread | -244 -248 1.69% | -284 -294 3.43% | -167 -163 -2.78% | -222 -218 -1.69% | -67,8 -58,6 -15.8% | 104 |
|
EBIT Million USD | Released Forecast Spread | -247 -248 0.48% | -287 -296 3.09% | -170 -166 -2.76% | -224 -220 -1.61% | -73,4 -62,1 -18.1% | 107 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -234 -238 1.56% | -281 -289 2.88% | -168 -164 -2.42% | -213 -213 0.02% | -51,0 -37,9 -34.55% | 109 |
|
Net income Million USD | Released Forecast Spread | -235 -238 1.29% | -282 -290 2.79% | -168 -164 -2.56% | -216 -212 -1.74% | -61,3 -54,9 -11.59% | 110 |
|
EPS USD | Released Forecast Spread | -1,60 -1,62 1.38% | -1,79 -1,84 2.81% | -1,05 -1,02 -3.12% | -1,34 -1,31 -2.2% | -0,37 -0,36 -2.89% | 0,63 |
| Announcement Date | 26/02/20 | 24/02/21 | 28/02/22 | 27/02/23 | 27/02/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 131 135 -3.42% | 115 122 -5.38% | 135 130 3.46% | 131 139 -5.99% | 136 135 0.97% | 118 120 -1.52% | 165 158 4.68% | 212 190 11.64% | 231 224 3.24% | 209 | 242 | 254 | 262 | 221 |
|
EBITDA Million USD | Released Forecast Spread | -44,1 -33,5 -31.61% | -112 -104 -8.09% | -33,0 -39,4 16.21% | -30,4 -36,0 15.59% | -45,6 -43,4 -4.94% | -53,2 -28,8 -84.58% | 4,80 8,30 -42.13% | -56,1 -64,6 13.21% | 36,6 45,9 -20.32% | 10,1 | 34,6 | 42,0 | 22,5 | |
|
EBIT Million USD | Released Forecast Spread | -44,7 -36,4 -22.72% | -113 -92,3 -22.45% | -33,7 -41,3 18.56% | -30,9 -30,5 -1.35% | -46,1 -41,5 -11.05% | -53,6 -38,1 -40.64% | 3,04 -10,7 128.28% | -57,8 -76,6 24.62% | 34,9 45,7 -23.46% | 6,29 | 33,1 | 38,2 | 31,0 | 59,7 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -42,9 -35,4 -21.07% | -113 -87,9 -28.12% | -33,6 -42,2 20.42% | -26,4 -30,1 12.22% | -40,9 -39,4 -3.83% | -44,9 -33,9 -32.68% | 6,34 -10,7 159.17% | -52,1 -76,1 31.44% | 39,7 54,2 -26.79% | 9,11 | 35,8 | 35,8 | 27,5 | 59,7 |
|
Net income Million USD | Released Forecast Spread | -43,1 -36,4 -18.55% | -113 -90,7 -24.68% | -34,0 -41,8 18.61% | -27,2 -29,5 7.87% | -41,7 -38,6 -8.12% | -43,0 -34,5 -24.53% | 1,11 -8,42 113.23% | -65,2 -76,1 14.34% | 45,8 53,1 -13.78% | 8,07 | 34,4 | 34,7 | 27,7 | 47,2 |
|
EPS USD | Released Forecast Spread | -0,27 -0,24 -14.89% | -0,70 -0,57 -21.95% | -0,21 -0,26 18.82% | -0,17 -0,19 9.86% | -0,26 -0,24 -8.02% | -0,27 -0,21 -29% | 0,01 -0,06 116.5% | -0,40 -0,45 10.93% | 0,28 0,30 -8.12% | 0,06 | 0,19 | 0,20 | 0,17 | 0,28 |
| Announcement Date | 28/02/22 | 04/05/22 | 08/08/22 | 02/11/22 | 27/02/23 | 08/05/23 | 02/08/23 | 02/11/23 | 27/02/24 | - | - | - | - | - |
More events
Past sector events for ACADIA Pharmaceuticals Inc.
| 26/04/2024 | GEMPHARMATECH CO., LTD.: Q1 2024 Earnings Release |
| 26/04/2024 | GEMPHARMATECH CO., LTD.: Q4 2023 Earnings Release |
| 26/04/2024 06:00 | BB BIOTECH AG: Q1 2024 Earnings Release |
| 25/04/2024 | BIDE PHARMATECH CO., LTD.: Q4 2023 Earnings Release |
| 25/04/2024 | PHARMARESOURCES (SHANGHAI) CO., LTD.: Q1 2024 Earnings Release |
| 25/04/2024 | HINOVA PHARMACEUTICALS INC.: Q1 2024 Earnings Release (Projected) |
| 25/04/2024 | BEIJING SUN-NOVO PHARMACEUTICAL RESEARCH CO., LTD.: Q4 2023 Earnings Release |
| 25/04/2024 | CHEMPARTNER PHARMATECH CO., LTD.: Q4 2023 Earnings Release |
| 25/04/2024 12:00 | MORPHIC HOLDING, INC.: Q1 2024 Earnings Release |
| 25/04/2024 07:00 | PURETECH HEALTH PLC: Q4 2023 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- ACAD Stock
- Calendar ACADIA Pharmaceuticals Inc.
